NYSE - Delayed Quote USD

Enovis Corporation (ENOV)

Compare
46.17 +1.39 (+3.10%)
At close: 4:00 PM EST
46.17 0.00 (0.00%)
After hours: 4:25 PM EST
Loading Chart for ENOV
DELL
  • Previous Close 44.78
  • Open 44.92
  • Bid 46.15 x 800
  • Ask 46.27 x 800
  • Day's Range 44.79 - 46.38
  • 52 Week Range 38.27 - 65.03
  • Volume 647,627
  • Avg. Volume 640,342
  • Market Cap (intraday) 2.58B
  • Beta (5Y Monthly) 2.00
  • PE Ratio (TTM) --
  • EPS (TTM) -2.21
  • Earnings Date Feb 20, 2025 - Feb 24, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 66.30

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

www.enovis.com

6,550

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ENOV

View More

Performance Overview: ENOV

Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ENOV
17.58%
S&P 500
24.72%

1-Year Return

ENOV
9.58%
S&P 500
30.82%

3-Year Return

ENOV
46.85%
S&P 500
26.62%

5-Year Return

ENOV
18.61%
S&P 500
91.37%

Compare To: ENOV

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ENOV

View More

Valuation Measures

Annual
As of 11/20/2024
  • Market Cap

    2.50B

  • Enterprise Value

    3.88B

  • Trailing P/E

    --

  • Forward P/E

    14.29

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.23

  • Price/Book (mrq)

    0.75

  • Enterprise Value/Revenue

    1.94

  • Enterprise Value/EBITDA

    21.84

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -5.95%

  • Return on Assets (ttm)

    0.37%

  • Return on Equity (ttm)

    -3.56%

  • Revenue (ttm)

    2B

  • Net Income Avi to Common (ttm)

    -121.38M

  • Diluted EPS (ttm)

    -2.21

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    35.42M

  • Total Debt/Equity (mrq)

    42.43%

  • Levered Free Cash Flow (ttm)

    -80.95M

Research Analysis: ENOV

View More

Company Insights: ENOV

Research Reports: ENOV

View More

People Also Watch